JAK Inhibitors for Psoriasis: A 2026 Overview

JAK inhibitors for psoriasis are a class of oral tablets that block an intracellular signaling step shared by many of the cytokines driving plaque psoriasis and psoriatic arthritis — offering a pill-based alternative to injectable biologics. Unlike biologics, which neutralize a single cytokine outside the cell, JAK inhibitors work from inside the cell, which is part of why this drug class carries both strong efficacy data and a safety conversation that every patient should understand before starting one. This overview explains how JAK inhibitors work, which drugs in this class are actually relevant to psoriatic disease in 2026, what the evidence shows, the FDA’s boxed warning, access and cost in India, and how this fits alongside Ayurvedic and integrative care.

What Are JAK Inhibitors and How Do They Work?

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are enzymes that sit just inside the cell membrane, underneath receptors for cytokines such as IL-23, IL-12, IL-6, and various interferons. When a cytokine docks onto its receptor, JAK enzymes activate STAT proteins, which travel to the nucleus and switch on the genes responsible for inflammation. In psoriasis and psoriatic arthritis, this pathway is chronically overactive. JAK inhibitors block the enzyme itself, shutting down signaling from several cytokines at once rather than just one — which is what makes them broader-acting than most biologics, for better and for worse.

Which JAK Inhibitors Are Actually Used for Psoriatic Disease?

Not every JAK inhibitor is approved for the same part of psoriatic disease, and this distinction matters more than most patients realize:

Tofacitinib (Xeljanz) — a pan-JAK inhibitor (predominantly JAK1/JAK3) approved for psoriatic arthritis and rheumatoid arthritis. It was studied in plaque psoriasis trials with positive skin results, but is not formally approved for skin-only plaque psoriasis in most markets. See our dedicated guide on tofacitinib for psoriatic arthritis for dosing, candidacy, and India-specific safety detail.
Upadacitinib (Rinvoq) — a more JAK1-selective inhibitor approved for active psoriatic arthritis (alongside rheumatoid arthritis, axial spondyloarthritis, and other immune conditions). Like tofacitinib, it targets joint disease rather than being approved specifically for plaque skin psoriasis.
Deucravacitinib (Sotyktu) — technically a TYK2 inhibitor rather than a conventional JAK1/2/3 inhibitor, and the one drug in this broader family specifically approved for moderate-to-severe plaque psoriasis. Its allosteric, TYK2-selective mechanism is different enough from tofacitinib and upadacitinib that it carries a distinct safety profile, which we cover in full in our deucravacitinib (Sotyktu) guide.

In short: if the main problem is joint inflammation (psoriatic arthritis), tofacitinib or upadacitinib are the relevant oral JAK options; if the main problem is skin-only plaque disease, deucravacitinib is the one in this family with a dedicated skin approval.

Who Is a Candidate for a JAK Inhibitor?

JAK inhibitors are generally considered for adults with moderate-to-severe psoriatic arthritis (or, for deucravacitinib, moderate-to-severe plaque psoriasis) who have had an inadequate response to conventional therapy such as methotrexate, who want an oral option rather than an injectable biologic, or for whom biologics are not accessible or affordable. Because of the safety profile discussed below, dermatologists and rheumatologists typically screen candidates carefully — checking for active or latent tuberculosis, hepatitis, cardiovascular risk factors, smoking history, prior blood clots, and any history of cancer — before prescribing, and these drugs are generally used more cautiously in patients over 65.

How Effective Are JAK Inhibitors for Psoriatic Disease?

Clinical trial data for this class is substantial. Tofacitinib’s phase 3 plaque psoriasis trials (OPT Pivotal 1 and 2) showed PASI 75 response rates in the range of roughly 40–65% depending on dose, meaningfully ahead of placebo, which is part of why it continues to be studied and used off-label for skin disease in some markets despite not carrying a formal plaque psoriasis indication everywhere. In psoriatic arthritis, both tofacitinib and upadacitinib have demonstrated clear, statistically significant improvements in joint symptoms (ACR20/50/70 response) and physical function compared with placebo in large randomized trials, with upadacitinib’s SELECT-PsA program also showing it performing comparably to, and in some measures better than, the biologic adalimumab on certain endpoints. Deucravacitinib’s own skin-clearance data, covered separately on this site, is strong enough that it has become a genuine alternative to apremilast for patients wanting an oral option.

Side Effects and the FDA Boxed Warning

This is the part of the JAK inhibitor story that deserves the most careful reading. In 2021, following results from the ORAL Surveillance post-marketing safety trial (conducted in rheumatoid arthritis patients aged 50 and older with at least one cardiovascular risk factor, comparing tofacitinib against TNF inhibitors), the US FDA added a class-wide boxed warning to tofacitinib, and subsequently to upadacitinib and baricitinib, covering an increased risk of major adverse cardiovascular events (heart attack, stroke), blood clots (venous thromboembolism, including DVT and pulmonary embolism), certain cancers including lymphoma and lung cancer, serious infections, and all-cause mortality in at-risk patients. As a result, regulators in the US and Europe now generally recommend these conventional JAK inhibitors be used only in patients who have not responded adequately to, or cannot tolerate, a TNF inhibitor, particularly in those 65 and older, smokers, or with pre-existing cardiovascular or clotting risk. Beyond the boxed warning, more routine side effects include upper respiratory infections, herpes zoster (shingles) reactivation at a notably higher rate than with biologics, elevated cholesterol, and changes in blood counts and liver enzymes — all of which require periodic monitoring. Deucravacitinib, because of its distinct allosteric TYK2-selective mechanism, has not been assigned this same boxed warning, which is a meaningful practical difference worth raising with your prescribing doctor.

Are JAK Inhibitors Available in India? Cost Considerations

Tofacitinib has been available in India as an affordable generic for several years, and in recent years Indian manufacturers such as MSN Laboratories have also launched generic upadacitinib (branded Upadoz) alongside generic tofacitinib (branded Tofadoz), specifically framed around improving affordability and access compared with imported originator pricing. This generally makes conventional JAK inhibitors meaningfully cheaper in India than most injectable biologics, though exact pricing varies by brand, strength, and pharmacy, and should always be confirmed directly with your prescribing hospital or pharmacy rather than estimated from online listings. For a fuller financial picture across psoriasis treatment options, see our psoriasis treatment cost guide.

JAK Inhibitors vs Biologics and Apremilast: How Do They Compare?

Against biologics, JAK inhibitors offer the convenience of a daily tablet instead of an injection, and their broader mechanism can address both skin and joint symptoms at once — but this same broad action is why they carry the cardiovascular, clotting, and cancer warnings that most biologics do not. Against apremilast, another oral option, conventional JAK inhibitors and deucravacitinib generally show stronger efficacy, though apremilast has a comparatively simpler safety profile with fewer monitoring requirements. For patients with predominantly joint disease who have already tried methotrexate, tofacitinib or upadacitinib remain reasonable options precisely because biologics may not always be accessible or affordable — a trade-off worth discussing directly with your psoriatic arthritis specialist given your personal risk profile, disease pattern, and budget.

How JAK Inhibitors Fit Into Ayurvedic and Integrative Psoriasis Care

An oral immune-modulating drug like a JAK inhibitor works by directly interrupting a cytokine signaling pathway, while Ayurveda approaches psoriasis through a slower, constitutional lens that looks at digestion, diet, stress, and lifestyle alongside the skin itself. At our Ayurvedic psoriasis clinic in Bangalore, we see patients across the full spectrum — some who are not yet candidates for a systemic drug, some who are actively on a JAK inhibitor and want integrative support for overall wellbeing and side-effect resilience, and some who have decided, after an informed conversation about the cardiovascular and clotting risk profile, that they would rather pursue an Ayurvedic-led approach first. Neither path is universally superior, and the right choice depends on disease severity, personal risk factors, and what matters most to you in daily life. We are happy to discuss where integrative care might reasonably fit alongside or instead of a JAK inhibitor during an in-person consultation.

This article is for general education and does not replace a consultation with a qualified dermatologist or rheumatologist. Candidacy, screening, dosing, and monitoring decisions — especially given the cardiovascular, clotting, and cancer risk considerations discussed above — should always be made directly with your treating doctor.

Frequently Asked Questions

1. What exactly is a JAK inhibitor?

A JAK inhibitor is an oral tablet that blocks Janus kinase enzymes (JAK1, JAK2, JAK3, or TYK2), which sit inside cells and relay signals from inflammatory cytokines like IL-23 and interferons. Blocking them reduces the inflammation that drives psoriasis and psoriatic arthritis.

2. Are JAK inhibitors approved for plaque psoriasis in India?

Tofacitinib and upadacitinib are primarily approved for psoriatic arthritis, not skin-only plaque psoriasis. Deucravacitinib, a selective TYK2 inhibitor in the same broader family, is the one specifically approved for moderate-to-severe plaque psoriasis, though its formal commercial availability in India is still limited.

3. What is the FDA boxed warning on JAK inhibitors about?

Following the ORAL Surveillance safety trial, the FDA added a boxed warning to tofacitinib, upadacitinib, and baricitinib covering increased risk of major cardiovascular events, blood clots, certain cancers, serious infections, and death in at-risk patients, particularly those over 50 with cardiovascular risk factors.

4. Is deucravacitinib affected by the same boxed warning?

No. Deucravacitinib’s allosteric, TYK2-selective mechanism is different enough from conventional JAK1/2/3 inhibitors that it has not been assigned the same class-wide boxed warning, though it still requires routine monitoring.

5. How much do JAK inhibitors cost in India?

Generic tofacitinib and, more recently, generic upadacitinib are manufactured in India, which generally makes conventional JAK inhibitors less expensive than most imported biologics. Exact pricing varies by brand and pharmacy and should be confirmed directly with your treating hospital.

6. Can JAK inhibitors be combined with Ayurvedic treatment?

Many patients use integrative approaches such as diet, stress management, and Ayurvedic skin support alongside a prescribed JAK inhibitor. Any combination should be discussed openly with both your treating doctor and your Ayurvedic practitioner to avoid unintended interactions.

Sources

Best Psoriasis Doctor in Bangalore - Dr Chaithanya KS

Article by Dr. Chaithanya KS

This article is provided for informational purposes and should not replace professional medical advice. Always consult with qualified healthcare providers before starting, stopping, or modifying any treatment protocol for psoriasis or other medical conditions.